Actively Recruiting
STRatIfication of Vulvar SCC by HPV and p53 Status to Guide Excision
Led by Canadian Cancer Trials Group · Updated on 2026-05-12
249
Participants Needed
11
Research Sites
363 weeks
Total Duration
On this page
Sponsors
C
Canadian Cancer Trials Group
Lead Sponsor
A
Australia New Zealand Gynaecological Oncology Group
Collaborating Sponsor
AI-Summary
What this Trial Is About
This study is being done to answer the following question: Are there types of early-stage vulvar cancer that require either less or more treatment than the usual approach?
CONDITIONS
Official Title
STRatIfication of Vulvar SCC by HPV and p53 Status to Guide Excision
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histologically confirmed diagnosis of vulvar squamous cell carcinoma (VSCC)
- Surgically staged FIGO I-II VSCC as per FIGO 2021 guidelines
- Vulvar resection performed according to standard care guidelines
- Post-operative assessment of tumour margin clearance, dVIN, and p53 status
- Participant is at least 18 years old
- Participant is able and willing to complete quality of life and health utility questionnaires in English or French
- Participant has given informed consent according to local and regulatory requirements
You will not qualify if you...
- Recurrent vulvar squamous cell carcinoma
- Non-squamous cell carcinoma types
- Receiving or previously received adjuvant vulvar radiation or chemotherapy
- Primary tumour HPV-independent p53 wild-type VSCC
- Surgical margins positive for invasive cancer
- History of other cancers except adequately treated non-melanoma skin cancer, treated in-situ cervical cancer, or other solid tumors with no evidence of disease for at least 5 years
- Lymph node positive VSCC or lymph nodes with isolated tumour cells
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 11 locations
1
BCCA - Kelowna
Kelowna, British Columbia, Canada, V1Y 5L3
Actively Recruiting
2
BCCA - Vancouver
Vancouver, British Columbia, Canada, V5Z 4E6
Actively Recruiting
3
Juravinski Cancer Centre at Hamilton Health Sciences
Hamilton, Ontario, Canada, L8V 5C2
Actively Recruiting
4
Odette Cancer Centre
Toronto, Ontario, Canada, M4N 3M5
Actively Recruiting
5
University Health Network
Toronto, Ontario, Canada, M5G 2M9
Actively Recruiting
6
CHUM-Centre Hospitalier de l'Universite de Montreal
Montreal, Quebec, Canada, H2X 3E4
Actively Recruiting
7
The Jewish General Hospital
Montreal, Quebec, Canada, H3T 1E2
Not Yet Recruiting
8
Hotel-Dieu de Quebec
Québec, Quebec, Canada, G1R 2J6
Actively Recruiting
9
CIUSSS de l'Estrie - Centre hospitalier
Sherbrooke, Quebec, Canada, J1H 5N4
Actively Recruiting
10
Allan Blair Cancer Centre
Regina, Saskatchewan, Canada, S4T 7T1
Actively Recruiting
11
Auckland City Hospital
Auckland, New Zealand, 1023
Actively Recruiting
Research Team
W
Wendy Parulekar
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here